Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2028

Conditions

Endometrial Cancer

Interventions

DRUG

Paclitaxel

Given by IV (vein)

DRUG

Carboplatin

Given by IV (vein)

DRUG

Dostarlimab

Given by IV (vein)

DRUG

Cisplatin

Given by IV (vein)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston